KemPharm, Inc. (KMPH) saw its loss widen to $12.23 million, or $0.84 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $2.93 million, or $0.20 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $7.38 million, compared with an operating loss of $6.97 million in the previous year period.
"Since the beginning of the year, we have continued to advance our clinical programs for KP415, KP201IR and KP511, and we believe we are now well positioned to meet the multiple clinical milestones that are anticipated throughout 2017 and into 2018," said Travis C. Mickle, Ph.D., president and chief executive officer of KemPharm. "Additionally, we continue to pursue the FDRR process with Apadaz with a potential resolution this year."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]